Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 5/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805091 | 0.81 | PTGS1 (0.46) | PTGS1POLBPARP1TSHR | |
| SCHEMBL2896682 | 0.79 | KDM4E (0.47) | PTGS1POLBCYP3A4MAPTCYP2C19 | |
| SCHEMBL4186879 | 0.76 | PTGS1 (0.37) | PDPK1PTGS1ROCK1TSHR | |
| SCHEMBL19418460 | 0.75 | PTGS1 (0.39) | PTGS1 | |
| SCHEMBL3979828 | 0.75 | ATM (0.49) | PTGS1SMN1; SMN2POLBPARP1TSHR | |
| SCHEMBL26334621 | 0.75 | PTGS1 (0.39) | PTGS1MAP4K4ROCK1CLK4 | |
| SCHEMBL26346889 | 0.71 | XDH (0.44) | SMN1; SMN2MAPTHSD17B10HPGDS | |
| SCHEMBL29511927 | 0.71 | NAMPT (0.44) | PDPK1NNMTPTK2PLK4CHEK1 | |
| SCHEMBL160863 | 0.71 | NAMPT (0.44) | PDPK1NNMTPTK2PLK4CHEK1 | |
| SCHEMBL2414968 | 0.70 | SMYD3 (0.47) | SMN1; SMN2TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-2539323-B3 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2017-10-04 | — | — | EP | disclosed |
| CN-103980258-B | Compounds as bradykinin B1 antagonists | 贝林格尔.英格海姆国际有限公司 | 2016-09-07 | — | — | CN | disclosed |
| CN-103980258-A | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2014-08-13 | — | — | CN | disclosed |
| CN-102781916-B | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2014-06-25 | — | — | CN | disclosed |
| US-8372838-B2 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| CN-102781916-A | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2012-11-14 | — | — | CN | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | PDPK1 3001/4885PTGS1 182/4885NNMT 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.